Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Tim SchmächeJuliane FohgrubAnna KlimovaKarin LaaberStephan DrukewitzFelix MerbothAlexander HennigTherese SeidlitzFriederike HerbstFranziska BaenkeAnne-Marlen AdaThomas GroßCarina WenzelClaudia R BallChristian PraetoriusThomas SchmidtBarbara Ringelband-SchillingRonald KoschnyAlbrecht StenzingerIngo RoederDirk JaegerSebastian ZeissigThilo WelschDaniela AustHanno GlimmGunnar FolprechtJürgen WeitzGeorg M HaagDaniel E StangePublished in: Molecular cancer (2024)
In vitro drug testing of EGC PDOs has a high predictive accuracy in classifying patients' histological response to neoadjuvant FLOT treatment. Taking into account the high rate of successful PDO expansion from biopsies, the definition of a threshold that allows treatment stratification paves the way for an interventional trial exploring PDO-guided treatment of EGC patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- clinical trial
- emergency department
- squamous cell carcinoma
- lymph node
- randomized controlled trial
- study protocol
- rectal cancer
- combination therapy
- replacement therapy
- locally advanced
- smoking cessation